

M Trifa, F Syed, D Tumin, JD Tobias, J Uffman
Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, Columbus, OHIO

Background

- Sugammadex: novel pharmacologic agent approved for clinical use by the United States FDA to reverse neuromuscular blockade (NMB) via encapsulating the muscle relaxant (rocuronium or vecuronium)
- Dosing is based on the degree of the NMB (train of four [TO4] monitoring) at the time of reversal.
- Review of our institution's documentation revealed that TO4 assessment prior to sugammadex administration was less common than anticipated, resulting in deviation from the manufacturer's dosing recommendations.
- The primary purpose of this study was to improve documentation of TO4 and secondarily to ensure the correct sugammadex dosing by anesthesia providers in a large tertiary care pediatric hospital.

Methods

Design: Retrospective review of patients' charts in whom the NMB was reversed by sugammadex.

Exclusion criteria:

- Patients < 1 year of age
- MRI cases, cases staffed by an attending anesthesiologist alone, and cases staffed by the project investigators.

Baseline data collection: (December 2016)

- Sugammadex dose
- Documentation of TO4 before and after sugammadex administration (patients with 4 twitches before NMB reversal did not require further TO4 documentation)

Interventions:

- Baseline provider level compliance was shared
- Electronic health record reminder was created
- Departmental level education regarding assessment and proper dosing regimens was provided.

Post-intervention data collection: (October 2017)

- Post-intervention chart review (same parameters)

Results

- One hundred cases were reviewed as baseline data and 75 cases were reviewed after interventions were completed.
- Prior to interventions, TO4 documentation was correct in 30 of 100 cases, and this proportion improved after intervention to 34 of 75 (45%; p=0.024).

Table: Appropriateness of twitch monitoring documentation before and after administering sugammadex by provider role

| Documentation | Hands-on anesthesia provider role | | | | p | |
|-----------------|---|-------------|---------------|-----------------|---------|-------|
| | CRNA (N=24) | SRNA (N=24) | Fellow (N=14) | Resident (N=13) | | |
| Appropriate | Twitch monitoring before and after sugammadex administration | 2 (8%) | 1 (4%) | 0 | 1 (8%) | 0.761 |
| | Twitch monitoring only before sugammadex administration with 4 responses on the TO4 | 10 (42%) | 11 (46%) | 2 (14%) | 7 (54%) | 0.144 |
| Not Appropriate | Twitch monitoring only before sugammadex administration | 4 (17%) | 4 (17%) | 4 (29%) | 3 (23%) | 0.781 |
| | Twitch monitoring only after sugammadex administration | 2 (8%) | 1 (4%) | 0 | 1 (8%) | 0.761 |
| | No twitch monitoring | 6 (25%) | 7 (29%) | 8 (57%) | 1 (8%) | 0.046 |

CRNA: Certified Registered Nurse Anesthetist, SRNA: Student Registered Nurse Anesthetist

- After intervention, reasons for incorrect TO4 documentation included missing TO4 before sugammadex administration (n=26) and <4 twitches documented before sugammadex administration with no subsequent TO4 documentation (n=15). However, there were no differences in appropriateness of TO4 documentation by provider role (Table).
- Among 49 cases where TO4 was documented before sugammadex administration, the dosing was correct in only 25 cases (51%), compared to 34 of 40 (85%) cases reviewed before intervention (p=0.001).
- Among post-intervention cases with TO4 documented before sugammadex administration, sugammadex was over-dosed (>110% of recommended) in 11 cases, but under-dosed (<90% of recommended) only in 2 cases.

Discussion

- Despite increased use of TO4 monitoring, the percentage remained low (45%) after educational interventions suggesting the need for other forms of interventions such as decision support for the electronic health record.
- The dosing of sugammadex remained variable and was considered correct based on TO4 monitoring in only 51% of patients.
- Excessive dosing was the most common error with only 2 of 49 patients receiving a dose <90% of the manufacturers recommendation based on degree of neuromuscular blockade.

References

1. Kim YB, Sung TY, Yang HS. Korean J Anesthesiol 2017;70:50010.
2. Asai T, Isono S. Anesthesiology 2014;120:260-2